<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We describe long-term disease-free survival (DFS) after unrelated donor bone marrow transplantation (BMT) for <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in 118 patients aged â‰¤18 years </plain></SENT>
<SENT sid="1" pm="."><plain>Forty-six patients had refractory cytopenia (RC), 55 <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), and 17 <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t) </plain></SENT>
<SENT sid="2" pm="."><plain>Transplant-related mortality was higher after mismatched BMT (relative risk [RR] 3.29, P = .002) </plain></SENT>
<SENT sid="3" pm="."><plain>Disease recurrence was more likely with advanced stages of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> at the time of BMT: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> (RR 6.50, P = .01) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t (RR 11.00, P = .004) </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment failure (<z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">recurrent disease</z:e> or <z:hpo ids='HP_0011420'>death</z:hpo> from any cause; inverse of DFS) occurred in 68 patients </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment failure was higher after mismatched BMT (RR 2.79, P = .001) and in those with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t (RR 2.38, P = .02) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">Secondary MDS</z:e> or chemotherapy prior to BMT was not associated with recurrence or treatment failure </plain></SENT>
<SENT sid="7" pm="."><plain>Similarly, cytogenetic abnormalities were not associated with transplant outcomes </plain></SENT>
<SENT sid="8" pm="."><plain>Eight-year DFS for patients with RC after matched and mismatched unrelated donor BMT was 65% and 40%, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Corresponding DFS for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t was 48% and 28%, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>When a matched adult unrelated donor is available, BMT should be offered as first-line therapy, and children with RC can be expected to have the best outcome </plain></SENT>
</text></document>